You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

~ Buy the ILEVRO (nepafenac) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR ILEVRO

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for ilevro

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01847638 ↗	Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery	Completed	Bausch & Lomb Incorporated	N/A	2013-04-01	To investigate inflammation, visual acuity and macular thickness after treatment with Prolensa vs Ilevro after cataract surgery.
NCT01847638 ↗	Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery	Completed	Melissa Toyos	N/A	2013-04-01	To investigate inflammation, visual acuity and macular thickness after treatment with Prolensa vs Ilevro after cataract surgery.
NCT01847638 ↗	Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery	Completed	Melissa Toyos, MD	N/A	2013-04-01	To investigate inflammation, visual acuity and macular thickness after treatment with Prolensa vs Ilevro after cataract surgery.
NCT02515045 ↗	Dropless vs. Standard Drops Contralateral Eye Study	Completed	Science in Vision	Phase 4	2015-01-01	To compare the use of an injectable compound containing an antibiotic and an anti-inflammatory at time of cataract surgery to standard of care that is the use 3 different topical medications to prevent inflammation and infection after routine cataract surgery.
NCT02515045 ↗	Dropless vs. Standard Drops Contralateral Eye Study	Completed	Carolina Eyecare Physicians, LLC	Phase 4	2015-01-01	To compare the use of an injectable compound containing an antibiotic and an anti-inflammatory at time of cataract surgery to standard of care that is the use 3 different topical medications to prevent inflammation and infection after routine cataract surgery.
NCT02752646 ↗	Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%	Completed	Alcon Research	N/A	2016-04-01	This study will examine the tolerability and toxicity of topically applied Nepafenac 0.3% vs ketorolac 0.5% among patients undergoing cataract surgery.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for ilevro

Condition Name

Chart
Table

Condition Name for ilevro
Intervention	Trials
Cataract	3
Grade of Post-Operative Cystoid Macular Edema	1
Inflammation	1
Patient Outcomes	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for ilevro
Intervention	Trials
Cataract	4
Inflammation	3
Papilledema	1
Macular Edema	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for ilevro

Trials by Country

Map
Table

Trials by Country for ilevro
Location	Trials
United States	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for ilevro
Location	Trials
Kentucky	1
California	1
South Carolina	1
New York	1
Minnesota	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for ilevro

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for ilevro
Clinical Trial Phase	Trials
Phase 4	3
N/A	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for ilevro
Clinical Trial Phase	Trials
Completed	4
Recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ilevro

Sponsor Name

Chart
Table

Sponsor Name for ilevro
Sponsor	Trials
Bausch & Lomb Incorporated	2
Churchhill Communications	1
Statistics & Data Corporation	1
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for ilevro
Sponsor	Trials
Other	9
Industry	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.